Anavex Life Sciences Corporation (AVXL) Options

NEXT WEEK NEWS REGARDING AVXL!!!

Good luck and GOD bless,

Pivoted to X (twitter) instead where there are less rules:

#Anavex Life Science’s #SIGMAR1 agonist supersedes cognitive and brain volume preservation over anti-amyloid treatments #Kisunla and #Leqembi in early #Alzheimer patients.

Under eval at #EMA, the drug targets disease 10-20 years prior to #amyloid. pic.twitter.com/ulttCHKgJk— MayoMobile (@SOTCanalytics) March 25, 2025

Reddit frustrates me! Mayomobile made a fantastic Reddit AVXL post yesterday. I spent 20 minutes on a detailed supportive response with links only to have it taken down a minute later.  Then even his post was deleted minutes after that also.  

For fun, I asked my unreliable research assistant ChatGTP to come up with any examples it could find of EMA-rejected drugs that were both highly efficacious and safe.

All it came up with was one FDA-approved drug that had somehow been approved on the basis of a 12 person uncontrolled trial and another rejected on the basis of cost and inaccessibility.

I also came across an article from about 10 years ago that reported that 85 to 90 percent of FDA approvals involved drugs that failed to demonstrate clinical effect.

This is just for amusement while we wait.

That you even understand the excellent description of the possibilities is

Not only unsurprising but predictable.

Finish Investing 101 before attempting another opinion.

Both regulators and potential patients will compare blarcamesine to the Anti-amyloid Mabs promoted by several Big Pharmas.

Trial data shows that blarcamesine is far safer both for early use and later use. Brain swelling and brain bleeds are associated with the Mabs and do not occur with blarcamesine.

And blarcamesine is more effective in both the short term and the longer term. Indeed it can delay alzheimers even before amyloid plaque is present and it can maintain brain volume while the Mabs eventually deplete it! It is significantly better at supporting cognitive ability both earlier and long term.

Blarcamesine will be far less costly than the Mabs and will not require the expensive and time consuming safety screenings!

Anavex has a drug which is clearly far safer, more effective and less costly. Both regulators, patients and their families will benefit.

And its Method of Action allow it to benefit many other Central Nervous System diseases. First Europe. Then the UK, Canada, Australia and Asia...and then the US when the new FDA guidelines are in place! Long and strong!

Maybe the Reddit crew will come in next Saturday after Dr. Timo Grimmer's presentation regarding the release of complete results from the Anavex blarcamesine OLE (open label extension) study!!! April 5, 2025 at e AD/PD 2025 conference.

Good luck and GOD bless,

Need a Reddit type infusion to break it upwards to $100.00

Do the math. 22 million shares short, at whatever share price you think they were shorted at, is a boat load of money. Somewhere between $160 - 200 million.

I'm pretty sure there are efforts to protect that amount of money.
Compared to the amount of money the shorts got for selling that 22 million shares, spending a few tens of thousands
to keep the SP in the range they want is a non-issue.

It sure appears that the shorts let the SP rise a bit and then short it back down adding more cash to the stash.

To me is looks like Anavex share price has a constant low level of pressure to rise. So all the shorts have to do is nothing for a bit, the SP rise to a target level they like and they short it back down. Rinse and repeat.

That looks like a pretty sound strategy.

Translation: CNN doesn't like him. 

How is he unpopular?

Agree. Stock wants to run but they won't let it. Somebody is spending a lot of money keeping this down..

Agreed. Daily chart with support horizontal zone and up channel.

https://investorshub.advfn.com/uimage/uploads/2025/3/25/rzyquScreen_Shot_2025-03-25_at_5.42.29_PM.png

5minute chart shows how each move with energy was getting smacked again today.

https://investorshub.advfn.com/uimage/uploads/2025/3/25/mzcujScreen_Shot_2025-03-25_at_5.47.47_PM.png

2925 is about right. Freudian slip?

There is only a small open interest in those OCT calls, so whatever was going on was a today only thing.

My guess is the shorts don't think the SP will go down, they will make it go down.

The open interest is small, so that was some arbitrage maybe. That is a lot of trading vol. Interesting that is was in calls & puts. I don't know enough about complex options trading to guess what that was about.

Which one has more UPSIDE???

Follow the money!!!

Dr.dolittle Hedgefunds at it again.

That post is absolute nonsense.

Expect AVXL stock to be priced significantly higher than it is currently by October 2925.

Good luck and GOD bless,

I hope democrats can get behind this, especially being it's toward unmet need diseases.

Those are indeed the possibilities. There is no way of knowing on which side of the options trades the mm was on as opposed to the non-mm entity. Thus, it could be either a long or a short bet, or a volatility (or lack thereof) play. 

Someone established either a long or short $12 strike straddle for October at a cost or sale of about 6.35.

Three possibilities I can think of:
1. If the driving force was someone establishing a long straddle they paid $6.35 expecting that the price will be EITHER > $18.35 or < $5.65. They could be comfortable with either outcome which would lead to a profit. They might be thinking - either the MAA is withdrawn (

If someone sold the $12 puts for ~$4.30 and bought the $12 calls for $2 then that is pretty much a wash at this price level: bullish because anything over $9.70 is profitable with accelerating profitability over $12.

Seems risky unless the 3-71 data is very strong because MAA will not be acted upon (approval or rejection) until March 2026.

Iborrowdesk site and AVXL is 20.1% there 20K shares available."To the Moon Alice" Shorts rammed the price down with 90K shares around 11:30AM today and the MOC came in at about 85K shares. We end up down a nickel. Yes, I grabbed a few of those cheap shares today. It is 5 O'clock somewhere. Time for a beer!
John k9uwa

I wouldn't hold my breath on legislation that has already failed multiple times, sponsored by an unpopular Senator. The information is more interesting for what it suggests is happening within the blarcamesine MAA process.

FYI: The up channel is still in force (it's a minor upwards channel that has been in force since the low below $8 (about 16 days, NO BREAKDOWN (yet)....what we have on the daily price chart is a "double back test" to the 50 day sma....yes, it's certainly possible to see the price drop to below that level, but as of now....no cigar for the bears!

It appears quite obviously that some people expect an approval by the EMA for Anavex’s blarcamesine to receive approval to begin selling in the over 2 dozen countries on the EU by or before October 2025.

Good luck and GOD bless,

Does that mean that the shorts think SP will go down further?
Or they're building The Short Covering of the Year?
Maybe both. : )

AVXL$$

Can anybody make some sense of the October 12 calls and puts? Some hedging probably but over 1000 contracts traded for each.

Wow....... so it means MAA approval = FDA approval if the "RESULT ACT" is passed.
Patiently waiting for the day
ANVX$$

I suspect that 2-73 may not be on the market in 10-15 years. 3-71 and other drugs will replace it, and that's a good thing. That means better results for people with CNS issues.

10 years is plenty of time for 2-73 to make Anavex a ton of money and help a lot of people.

2-73 may not be worth much in 10 years and Anavex will be worth a whole lot.

First we need approval !!!!

I just checked the Iborrowdesk site and AVXL is 20.1% there with 20K shares available.

Exactly. One could also say that your individual vote is immaterial to an election. True. But collectively they matter. 

"Blarcamesine Market Set To Reach USD 1,082.8 Million By 2032, At A CAGR Of 4.0% Research By Coherent Market Insights"

(MENAFN- EIN Presswire)
Blarcamesine Market Growth 2025

The Global blarcamesine market will be valued at US$ 822.9 Mn in 2025 and is expected to reach US$ 1,082.8 Mn by 2032, exhibiting a CAGR of 4.0% from 2025- 2032

BURLINGAME, CA, UNITED STATES, March 2025 /EINPresswire / --
The Latest comprehensive Research Report on the Global Blarcamesine Market 2025-2032, Outlook is performed by determining industry drivers, dynamics, value chain analysis, prominent investment areas, competitive landscape, regional outlook, and key market segments. It also offers a thorough assessment of the global market's drivers and constraints. The Global Blarcamesine Market report has been designed after a Research Scope and Methodologies of various segments such as share, demand analysis, growth figure, SWOT Analysis and recent trends and so on. Furthermore, this report comprises important statistics, opportunities current industry trends, new innovations, upcoming updates, and the market environment.

The primary objective of this report is to provide readers with an in-depth market analysis, equipping them with the insights needed to develop effective growth strategies, assess the competitive landscape, evaluate their market position, and make informed business decisions in the Global Blarcamesine Market. It delivers key projections on essential factors such as market size, production, revenue, consumption, CAGR, gross margin, and pricing. The report is based on the most reliable primary and secondary research methodologies and sources. Additionally, it includes a range of research studies covering market dynamics, pricing trends, production and consumption patterns, company profiles, and manufacturing costs.

Request Sample Copy of Report @

Scope of Global Blarcamesine Market Report:

The Global Blarcamesine Market Report presents a detailed analysis of trends, drivers, and challenges within the industry. It includes thorough insights into market segmentation by product type, application, and geography. The report highlights major players and their competitive strategies, as well as emerging opportunities for growth. It also investigates consumer behavior and preferences that affect market dynamics. Forecasts for market size and growth potential in the upcoming years are included, backed by quantitative data. It also addresses regulatory factors and technological advancements influencing the market, making this report a valuable resource for stakeholders looking to make informed business decisions.

The Global Blarcamesine Market report covers the Top Key Players.

Anavex Life Sciences - Segmentation and Classification:

- By Route of Adminsitration: Oral, Parenteral
- By Application: Alzheimer's Disease, Parkinson's Disease , Dementia, Rett Syndrome, Others
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Geographical Landscape of the Global Blarcamesine Market:

The Market report provides in-depth insights into the market landscape, breaking it down into sub-regions and individual countries. This section of the report not only showcases the market share of each country and sub-region but also uncovers potential profit opportunities within these areas.

)) North America (United States, Canada, and Mexico)
)) Europe (Germany, France, UK, Russia, Italy)
)) Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
)) Latin America (Brazil, Argentina, Colombia)
)) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Reasons to buy Global Blarcamesine Market research report:
¦ Access to valuable information: Global Blarcamesine Market research report provides access to valuable information and data that can help to make informed decisions.

¦ Gain competitive intelligence: Global Blarcamesine Market research report provides insights into the competitive landscape, including information on the leading players, their market share, and their strategies. This can help businesses develop effective strategies for competing in the market.

¦ Make informed investment decisions: Global Blarcamesine Market research report provides valuable insights for users, including analysis of market trends, growth potential, and risks. This can help to make investment decisions and minimize their risk.

¦ Stay up-to-date on industry developments: Global Blarcamesine Market research report also provides regular updates on industry developments, including new product launches, mergers and acquisitions, and regulatory changes. This can help users to stay ahead of the curve and adapt to changing market conditions.
Report Includes Following Questions:

What will be the size of the Global Blarcamesine Market in the coming years?
2. Which segment will top the Global Blarcamesine Market?
3. What are the primary driving factors of the global Market?
4. What is the nature of the competitive landscape of the Global Blarcamesine Market?
5. What are the go-to strategies accepted in the Global Blarcamesine Market?
6. What are the key driving factors of the global Global Blarcamesine Market?
7. Which are the dominant players of the Global Blarcamesine Market?
8. How will the market development trends change in the next five years?

Strategic Points lined in Table of Content of Global Blarcamesine Market:

- Chapter 1: Introduction, market actuation product Objective of Study and analysis Scope the world Global Blarcamesine Market (2025-2032).

- Chapter 2: Exclusive outline - the fundamental info of the world Global Blarcamesine Market.

- Chapter 3: Ever-changing Impact on Market Dynamics- Drivers, Trends and Challenges & Opportunities of the world Global Blarcamesine Market Analysis.

- Chapter 4: Presenting the world Global Blarcamesine Market correlational analysis, Porters 5 Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

- Chapter 5: Displaying the by kind, user and Region/Country 2025-2032.

- Chapter 6: Evaluating the leading makers of the world Global Blarcamesine Market that consists of its Competitive Landscape, generation Analysis, BCG Matrix & Company Profile.

- Chapter: To estimate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these numerous regions (2025-2032).

... To be continued

Author of this marketing PR:
Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, have a sales office at global financial capital in the U.S., and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed to playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:

Mr. Shah
Coherent Market Insights Pvt. Ltd.
+ 12524771362
email us here
Visit us on social media:
Facebook
X
LinkedIn

This argument is a variant of the one Investor uses to argue against the fact that ~83 percent of all MAA applications get approved.

The argument here is that aggregate behavior is what counts, not individual actions. We contribute to a greater function, a public marketplace, that has helped Anavex to exist as a company. And, yes, no individual's decision is at all determinative. Both things are true.

Anavex wouldn't have sent Nell Rebowe to meet with Ted Cruz to support his RESULT Act had they received an 80 day letter last week that informed the company its MAA would be disapproved because there was only one 2b/3 AD trial. (Not that such a negative statement was ever in the cards.)

Probably because their small open label P2a trial sleep and other data was only indicative and doesn't all hold up in a larger RCT.

Looking at the larger chart picture, intermediate term pattern, time periods of a few months to half year, to a year...the larger waves... not short term trade waves. ... the latest wave was a rally from the 7.80 area to 10.20 area. Also like saying 8 to 10. The 50% Fib pullback targets 9.00 area, and overshoot looks at 8.75 area. Those can be considered normal pullback targets. In play now. as is the first step along the way, 9.25 area.

Unfortunately the peer reviewed article in JPAD does not give us sleep data as it was not a secondary end point. I wonder if we will ever see that data.

No sleep data has been reported. Disclosure, if positive, is unlikely to move the needle much. More likely, the data is non-significant, and won't ever be released. The 2b/3 had two sleep scales measured at baseline and every 12 weeks, the RSCAQ (retrospective sleep continuity assessment questionnaire) and the ISI (Insomnia severity index). These can give a measure of sleep quality and insomnia but are subjective, reported by the patient in the morning. The study did not include PSG or actigraphy that capable of objectively measuring or inferring wakefulness, NREM and REM sleep time/percent, respectively. Multiple studies have shown an association with sleep disturbances including reduced Stage 3 NREM sleep in the development and perhaps progression of AD. I would not hold my breath for the sleep scale data. 5 years out, we still have not seen the actigraphy data from the PDD.

The company has not made mention of it lately but in the past it noted improved sleep as one of the secondary effects of Blarcamasine.

Poor sleep behavior is a common complaint among AD sufferers.
This article indicates non REM sleep as a component of the process by which memories are stored and would be relevant in AD.

Unfortunately the peer reviewed article in JPAD does not give us sleep data as it was not a secondary end point. I wonder if we will ever see that data.

Yes, I see that too. Ugly looking plunge. From Resistance area 9.60/9.70, that I noticed to anticipate. The peak of the rally at 10.20/10.15/10.00/rolling over at 9.85 area, and plunging down yesterday to 9.30, looked a little harsh as well... and confirmed this pullback wave. I had marked the target area as 9.50/40/30 ... which happened to bounce at 9.30. So here we are now fumbling around 9.40 area. Below 9.30 would look like 9 dollars to me, and technical buy target zone 9.00/8.80/8.70. I see some chart points , moving avg. there.

You are simply a stone on the stream bed. The water flows around and above you (and me.) The notion that you are important is, IMO, incorrect. Your point is that somehow you (we) are important to the overall market for Anavex shares and that is important for Anavex when they sell more shares. But, no...the material state of the business is what sets the price. We are not material ourselves as investors. You (and I) could sell our shares in 5 minutes and it would make no difference excapt in a small way for a very short time.

The tricksters continue.
1minute chart shows normal trading. Then someone cannot stand 9.61 as support and blasts price heavily. Heavy hand still pushing down and currently price hits 9.40 low. Nasty bears, especially with news expectation and price moving so well last 3 weeks.

https://investorshub.advfn.com/uimage/uploads/2025/3/25/hrrcdScreen_Shot_2025-03-25_at_9.34.18_AM.png

Here is a 3 day 5minute view of their shenanigans.

https://investorshub.advfn.com/uimage/uploads/2025/3/25/bkglsScreen_Shot_2025-03-25_at_9.41.15_AM.png

Maurice Tangui has been around for a very long time. He's too old to bring anything to the finish line, so I think he's looking to cash in by selling his new company if he manages to make any progress.

"We welcome SAVA investors!"

1. Very few of them have any money any more.

2. They were never investors.

How Sleep Rewrites the Brain to Strengthen and Optimize Memories

https://neurosciencenews.com/sleep-memory-optimization-28509/

Good luck and GOD bless,

Your answer is probably as good as mine - almost!

Does that mean our AVXL shares will be wortless in 10–15 years?

Options purchase is treated as Cap Gains rates... as long as he then holds all for some period of time. His rate would be 24% or else 19% depending on his taxable income. definitely not 50%.
John k9uwa